title: Trying to harness the potential of HDL: wishful thinking or sound strategy?
authors.affiliation: Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1736, USA afogelman@mednet.ucla.edu.
authors.forename: Alan M
authors.initials: AM
authors.lastname: Fogelman
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D016632:Apolipoprotein A-I / Q000008:administration & dosage*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010743:Phospholipids / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage*
chemical_list: D016632:Apolipoprotein A-I; D002317:Cardiovascular Agents; D010743:Phospholipids; D011994:Recombinant Proteins